Achilles Therapeutics Plc ADR (ACHL) concluded trading on Tuesday at a closing price of $1.14, with 2.25 million shares of worth about $2.56 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 32.87% during that period and on December 24, 2024 the price saw a gain of about 16.18%. Currently the company’s common shares owned by public are about 41.10M shares, out of which, 37.95M shares are available for trading.
Stock saw a price change of 15.83% in past 5 days and over the past one month there was a price change of 5.67%. Year-to-date (YTD), ACHL shares are showing a performance of 26.00% which increased to 36.55% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.63 but also hit the highest price of $1.76 during that period. The average intraday trading volume for Achilles Therapeutics Plc ADR shares is 130.51K. The stock is currently trading 10.77% above its 20-day simple moving average (SMA20), while that difference is up 11.15% for SMA50 and it goes to 24.15% higher than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Achilles Therapeutics Plc ADR (NASDAQ: ACHL) currently have 41.10M outstanding shares and institutions hold larger chunk of about 51.57% of that.
The stock has a current market capitalization of $46.04M and its 3Y-monthly beta is at 1.37. It has posted earnings per share of -$1.66 in the same period. It has Quick Ratio of 6.04 while making debt-to-equity ratio of 0.04. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ACHL, volatility over the week remained 7.82% while standing at 4.47% over the month.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Piper Sandler on April 05, 2024 offering a Neutral rating for the stock and assigned a target price range of between $8 and $2 to it. Coverage by Piper Sandler stated Achilles Therapeutics Plc ADR (ACHL) stock as an Overweight in their note to investors on April 26, 2021, suggesting a price target of $25 for the stock. On April 26, 2021, Oppenheimer Initiated their recommendations, while on April 26, 2021, JP Morgan Initiated their ratings for the stock with a price target of $11. Stock get a Buy rating from Chardan Capital Markets on April 26, 2021.
